- COC-Certified Oncology Coders
Specialized Billing for High-Risk, High-Complexity Cardiology Practices
oncology billing isn’t “regular billing.” It’s high-risk, high-volume, modifier-heavy, and utterly unforgiving. One coding error, one missed authorization, or one documentation gap—and thousands in revenue vanish. Neo MD fixes that with oncology-certified billers, clean claims from day one, and aggressive denial recovery built for chemo, infusion, and radiation workflows.
97-99%
Clean Claim Rate
+22%
Revenue Increase
90 Days
To See Results
- Practice Revenue Health Audit
Is Your Oncology Practice
Bleeding Revenue? (Most Are.)
If you fall behind your revenue goals, it’s time to get our professional consultation about the Revenue Cycle Management process. If any of these are happening, you’re losing $200K–$500K+ annually:
Visible Revenue Bleed
Immediate Impact
Chemo Infusion Claims Denied
JW/JZ wastage modifiers applied incorrectly
Drug Administration Claims Rejected
Infusion sequencing errors (96360-96417 series)
Immunotherapy Claims Denied
Missing medical necessity documentation
High-Cost Drug Claims Delayed
Prior authorization failures are holding up treatment
Biosimilar Claims Bundled
When they should've been billed with Q-codes separately
NDC Format Violations
Triggering automatic denials on drug claims
Invisible Losses
According to MGMA and COA oncology benchmarking data, practices lose 18%–25% of revenue due to:
1 unit ≠ 1 mg confusion
Chemo Drug Unit Errors
Initial vs subsequent coding
Infusion Time Documentation
Service sequencing errors
Hydration vs Therapeutic
JW/JZ modifier missing
Drug Wastage Reporting
Wrong code selection
Biosimilar Q-Code Errors
Incorrect treatment series
Multi-Day Regimen Billing
ICD-10 pairing failures
Diagnosis-to-Drug Linkage
Incomplete documentation
Growth Factor Injections
"You didn't train for 10+ years to fight with insurance companies. But right now, coding errors cost more than a mid-level provider's salary."
$500,000+
- Industry Problem
Why General Medical Billing Companies Fail Oncology Practices
Oncology billing requires specialty expertise that general billers don’t have.
Chemo infusion coding chaos
Can't determine the correct administration code hierarchy
Drug unit calculation blindspot
Misapply unit conversions constantly
NDC formatting confusion
Don't understand 11-digit format requirements
Initial vs subsequent miss
Can't distinguish infusion code types (96413 vs 96415)
Wastage documentation underbilling
Don't understand JW/JZ modifier requirements
Medical necessity gaps
Can't track immunotherapy justification
Multi-drug regimen errors
Undercode complex chemotherapy protocols
LCD policy blindspot
Don't track coverage determinations by diagnosis
Result: 15%–22% denial rates, 45-60 day payment cycles, and constant staff time wasted on resubmissions.
- The NEO MD Difference
The NEO MD Oncology Advantage
Specialty-Exclusive Billing Built for Complex Oncology Workflows.
Oncology-Certified Billing Teams
- All billers are oncology-trained and certified
- Deep expertise in chemo infusion, immunotherapy, and targeted therapy
- Correct coding across 96401–96417, J-codes, Q-codes, and wastage reporting
→ 96% first-pass acceptance rate
Full Prior Authorization Management
- Chemotherapy (all regimens)
- Immunotherapy
- Radiation oncology
- Diagnostic imaging
- Genetic testing
→ Average PA turnaround: 48–72 hours
→ No more treatment delays
→ No more revenue freezes
Oncology-Specific Denial Prevention
- NDC formatting & units
- JW/JZ wastage compliance
- LCD medical necessity
- Sequencing of infusion services
- Diagnosis-to-drug pairing
→ Denials drop below 4% in 60 days
Maximum Reimbursement Coding
- Correct hierarchy of infusion codes
- Proper billing of hydration/therapeutic/chemo
- Capture of prolonged infusion
- Correct revenue units for high-cost drugs
- Documentation support for medical necessity
→ Average +22% revenue increase in 90 days
Complete Revenue Transparency
- Real-time dashboards
- Weekly performance reports
- Monthly revenue strategy calls
- Quarterly compliance audits
→ You always know where your money is.
- Proven Results
Performance Benchmarking
Neo MD Versus Industry Standards
| Performance Metric | National Oncology Benchmark | Neo MD Client Average |
|---|---|---|
| Clean Claim Rate | 82–87% | 97–99% |
| Initial Denial Rate | 12–18% | 3–6% |
| Days in A/R | 42–55 days | 24–32 days |
| Collection Rate (Net) | 94–96% | 98–99.5% |
| Drug Reimbursement Accuracy | 87–92% | 98–99% |
| Prior Auth Approval Rate | 76–83% | 94–97% |
| Prior Auth Turnaround | 7–12 days | 2–4 days |
Oncology Services & Treatment Types We Bill With Zero Errors
Chemotherapy
IV infusion (initial, subsequent, prolonged)
Chemo multi-drug regimens
Oral chemotherapy management
Intrathecal chemotherapy
Immunotherapy & Targeted Therapy
Keytruda, Opdivo, Yervoy
CAR-T therapy coding
Monoclonal antibodies
Biosimilars (specific Q-codes)
Radiation Oncology
IMRT
SBRT
IGRT
Proton therapy
Hematology Services
Iron infusion (Venofer, Injectafer)
Blood transfusions
Growth factor injections (Neulasta, Neupogen)
Diagnostic & Treatment Support
- PET/CT
- Genetic testing
- Biopsies
- Lab billing with CLIA compliance
Real Results
Oncology Clinic — 4 Providers
( Florida )
- Before NEO MD
Denial Rate
21%
Days to Payment
56 days
Annual Loss
$310K
Staff overwhelmed by prior auth delays
- After 90 Days
Denial Rate
4.2%
Days to Payment
22 days
Monthly Revenue
$48,000
Staff freed to focus on patients
“We didn’t realize how much revenue was leaking until NEO MD fixed our infusion billing. It’s night and day.”
— Dr. Elaine H., Medical Oncologist
Mid-Page CRO Lead Magnet: Free Oncology Revenue Leak Report
This report is worth $1,500 — yours free.
Get a free audit that identifies:
- Revenue lost to drug wastage errors
- Incorrect infusion administration codes
- Denial patterns in your chemo claims
- Missed NDC-to-drug matches
- Prior auth bottlenecks
- Incorrect biosimilar coding
How We Increase Oncology Revenue in 90 Days
We evaluate denials, drug units, NDC errors, infusion coding, and payer-specific issues.
No downtime. No lost claims.
Correct coding → PA workflow → denial elimination → faster payments.
Compliance checks, quarterly audits, documentation training, and ongoing coding updates.
Critical Compliance Issues We Handle
Oncology is heavily audited. We protect your practice by managing:
JW/JZ wastage reporting
NDC unit accuracy
LCD policies for cancer diagnostics
Medical necessity documentation
Biosimilar coding rules
Prior authorization logs
CLIA compliance
OIG audit readiness
We keep you compliant, paid, and audit-ready.
Frequently Asked Questions
No — we transition you in 10–14 days without missing a claim.
Yes — all regimens, all payers.
Yes — we work with all major oncology systems.
5%–7% of collections — typically yielding +20% more revenue.
Stop Losing $200K–$500K+ Every Year to Oncology Billing Errors
Every month you stay with a general billing company, you lose
- Revenue from chemo infusion errors
- Revenue from NDC mismatches
- Revenue from failed prior auths
- Revenue from improper sequencing
- Revenue from missing wastage documentation
Switching to NEO MD pays for itself in the first 30 days.
Stop Oncology Revenue Leakage. Start Earning What You Deserve.
Oncology billing isn’t supposed to drain your time, your team, or your revenue.
If denials, authorizations, chemo coding, or documentation issues are costing you money, it ends here.NEO MD’s oncology-trained billers deliver higher first-pass approvals, cleaner claims, faster reimbursements, and predictable cash flow — without disrupting your practice.
You Get:
- Oncology-certified billers & coders
- Faster chemo/infusion prior auths
- Better documentation guidance
- HIPAA, OIG, CMS compliance
- Immediate onboarding — no downtime
- Real-time revenue reporting